On Friday, Shares of Duke Energy Corp (NYSE:DUK), subtract -0.94% and closed at $77.21 in the last trading session. The last trading range of the stock ranges between $77.18 and $77.98. Site inspections at the H.F. Lee Power Plant in Goldsboro, N.C., recently confirm there was only very minor erosion of material from an inactive coal ash basin on the site.
The majority of that material, which includes coal ash, remained very close to the inactive basin, on the berm or a few feet away on the basin roadway.
The state team that inspected the facility determined that the amount of material that was displaced would not even fill the bed of an average pickup truck.
Water samples taken on Oct. 12, just downstream of the inactive basins, showed no measurable ash-related constituents in the Neuse River.
The inactive basins have well-established cover – counting organic material, grass, shrubs and trees – and have performed as expected in the aftermath of Hurricane Matthew with minimal erosion.
Time Warner Inc (NYSE:TWX), jumped 0.19% and closed at $79.55 in the last trading session. The last trading range of the stock ranges between $79.21 and $80.08. The company’s Market capitalization is $61.99 Billion with the total outstanding Shares of 777.84 million. Time Warner Inc. operates as a media and entertainment company in the United States and internationally. It operates through three segments: Turner, Home Box Office, and Warner Bros. The Turner segment owns and operates a portfolio of cable television networks and related properties that offer entertainment, sports, kids, and news programming on television and digital platforms for consumers. It operates about 180 channels in 200 countries. The Turner segments networks and related properties include TNT, TBS, Adult Swim, truTV, Turner Classic Movies, Turner Sports, Cartoon Network, Boomerang, CNN, and HLN; and digital media properties comprise bleacherreport.com, NBA.com, NBA Mobile, NCAA.com, PGA.com, tntdrama.com, TBS.com, adultswim.com, and cartoonnetwork.com. It also licenses original programming to subscription-video-on-demand (SVOD) services and other over-the-top services, and its brands and characters for consumer products other business ventures. This segment serves cable system operators, satellite service distributors, telephone companies, and other distributors. The Home Box Office segment provides premium pay and basic tier television services comprising HBO and Cinemax; sells its original programming through physical and digital formats; and licenses home entertainment and content to international television networks and SVOD services. As of December 31, 2015, this segment had 49 million domestic subscribers. The Warner Bros. segment produces, distributes, and licenses television programming and feature films; distributes digital and physical home entertainment products; and produces and distributes videogames, in addition to licenses consumer products and brands. The company was formerly known as AOL Time Warner, Inc. and changed its name to Time Warner Inc. in 2003.
StemCells Inc (NASDAQ:STEM), lost -0.96% and closed at $1.03 in the last trading session. The last trading range of the stock ranges between $1.01 and $1.10. The company’s Market capitalization is $12.25 Billion with the total outstanding Shares of 12.01 million. During the 52-week trading session the minimum price at which share price traded, registered at $0.33 and reached to max level of $7.56. StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and related technologies. It develops HuCNS-SC platform technology, a purified human neural stem cells used as a potential therapeutic to treat diseases and disorders of the central nervous system. The companys HuCNS-SC is in Phase I clinical trials for the treatment of Pelizeaus-Merzbacher Disease; and has accomplished a Phase I clinical trial for infantile and late infantile neuronal ceroid lipofuscinosis. Its HuCNS-SC is also in Phase I/II clinical trials for the treatment of thoracic spinal cord injury; Phase II clinical trials for the treatment of cervical spinal cord injury; and Phase I/II clinical trials for dry age-related macular degeneration.